Please upgrade your browser.
Small kidney tumours have an agressive potential and should be treated, according to the results of a large multicentre study presented at the 28th Annual EAU Congress in Milan.
“By working with others who specialize in helping people whose lives have been touched by renal cancers, we’ve made remarkable strides in the development of new medicines, along with advancements in surgical interventions, and helping patient families with the psycho-social aspects of dealing with the disease.”
The Cost of Hope: A Candid Roundtable Discussion. ABC News veteran and anchor, Sam Donaldson, moderated the opening session, as he has for the past seven years, following a keynote address from Amanda Bennett, Pulitzer Prize-winning journalist, Executive Editor, Bloomberg News, and author of The Cost of Hope: A Memoir, who spoke candidly about her late husband, Terence Foley, and his battle with kidney cancer.
Although more than 100 soldiers have filed claims for health issues they believe stem from their exposure to Agent Orange while serving in Gagetown, all have been unsuccessful.
Scientists investigate potential markers for a response to sunitinib in patients with metastatic RCC
Markers such as CA9, CD31, CD34 and VEGFR1/2 in the primary tumours might serve as predictors of a good response to a sunitinib treatment in patients with metastatic clear cell renal cell carcinoma (ccRCC), according to a new study to be presented at the 28th Annual EAU Congress currently on-going in Milan.
Data detailed on Kidney Disease have been presented. According to news reporting from Taipei, Taiwan, by NewsRx journalists, research stated, "Spontaneous perinephric hemorrhage is a clinically rare life-threatening condition, also known as Wunderlich syndrome. Presentations can be variable, but patients typically display symptoms and signs including flank or abdominal pain, abdominal mass, and hypovolemia."
The conference will be open to all, but is primarily for kidney cancer patients and their families. The conference will be sponsored by the Kidney Cancer Association and chaired by Dr. Christopher G. Wood, Professor and Deputy Chairman, Department of Urology.
KCA CEO, Bill Bro, a 24-year kidney cancer survivor, serves as a member of NCI’s Renal Cancer Task Force, as well as an adviser to the Kidney Cancer SPORE, a federally funded program of research excellence based in Boston.
Scientists have hailed the finding “unexpected and exciting”.
Legislation has been introduced in Springfield that would help open the door to a new generation of medicines that could help treat kidney cancer and other chronic, debilitating diseases.
|NeonCRM by Neon One|